XSHG
600351
Market cap705mUSD
Oct 09, Last price
7.07CNY
1D
3.67%
1Q
12.94%
Jan 2017
-28.44%
IPO
180.56%
Name
Yabao Pharmaceutical Group Co Ltd
Chart & performance
P/E
15.29
P/S
2.18
EPS
0.46
Div yield, %
4.40%
Shrs. gr., 5y
-2.02%
Rev. gr., 5y
-2.95%
Revenues
2.24b
-16.60%
Net income
320m
+31.86%
CFO
574m
+21.64%
Dividend
Sep 01, 20260.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Beijing, China.
Key people
Wuxian Ren
Chairman of the Board, General Manager · since 2017
Zhefeng Zuo
Chief Financial Officer · since 2017
Jun Liang
Deputy General Manager
Pengbo Ren
Deputy General Manager · since 2017
Wei Ren
Deputy General Manager · since 2017
Ke Tang
Executive Deputy General Manager · since 2017
Yuhong Yu
Chief Engineer · since 2008
Gang Wang
Secretary of the Board · since 2017
Jiangming Guo
Director · since 2011
Director · since 2008
Independent Director · since 2008
Independent Director · since 2008
Cheng Zhang
Independent Director · since 2008
Henglin Zhao
Independent Director · since 2008
Headquarters & legal address
芮城县富民路43号
运城市, SX 044600
CN
运城市, SX 044600
CN
Address
43 Fumin Rd, Ruicheng
Yuncheng, SX 044600
CN
Yuncheng, SX 044600
CN
Other language
YABAO Pharmaceutical Group Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||